• AKT inhibitor
• capivasertib based treatment
• capivasertib plus paclitaxel
• ipatasertib based treatment
• ipatasertib plus paclitaxel
• antibody–drug conjugate
• sacituzumab govitecan
• trastuzumab deruxtecan
• trastuzumab emtansine
• trastuzumab emtasine plus endocrine therapy
• aurora kinase inhibitors
• alisertib plus paclitaxel
• biguanide
• metformin
• celecoxib plus endocrine therapy
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus aromatase inhibitor
• abemaciclib plus endocrine therapy
• abemaciclib plus fulvestrant
• dalpiciclib plus fulvestrant
• palbociclib based treatment
• palbociclib
• palbociclib plus endocrine therapy
• palbociclib plus fulvestrant
• palbociclib plus letrozole
• ribociclib based treatment
• ribociclib plus endocrine therapy
• ribociclib plus fulvestrant
• ribociclib plus letrozole
• endocrine therapy
• androgen deprivation therapy (ADT)
• abiraterone plus ADT
• abiraterone plus docetaxel plus ADT
• apalutamide plus ADT
• darolutamide plus doxetaxel plus ADT
• docetaxel plus ADT
• enzalutamide
• enzalutamide plus ADT
• gene alteration target therapy
• BRAF gene alteration targeted therapy
• BRAF inhibitor
• combined BRAF-MEK inhibitors
• trametinib plus dabrafenib
• KRAS gene alteration targeted therapy
• sotorasib
• MET gene alteration targeted therapy
• capmatinib
• NTRK gene alteration targeted therapy
• entrectinib
• larotrectinib
• RET gene alteration targeted therapy
• pralsetinib
• selpercatinib
• HDAC inhibitor
• entinostat plus exemestane
• tucidinostat based treatment
• tucidinostat plus exemestane
• HER inhibitor
• EGFR inhibitor
• afatinib based treatment
• afatinib plus vinorelbine
• HER2 inhibitor
• neratinib based treatment
• neratinib
• neratinib plus capecitabine
• pertuzumab based treatment
• pertuzumab plus trastuzumab
• pertuzumab plus trastuzumab plus docetaxel
• trastuzumab based treatment
• docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
• trastuzumab plus endocrine therapy
• trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
• tucatinib based treatment
• tucatinib plus trastuzumab plus capecitabine
• TKI anti HER1/EGFR and HER2/neu
• lapatinib based treatment
• lapatinib
• lapatinib plus capecitabine
• lapatinib plus fulvestrant
• lapatinib plus letrozole
• lapatinib plus paclitaxel
• lapatinib plus trastuzumab
• lapatinib plus trastuzumab plus paclitaxel
• IGF-1R inhibitors
• dalotuzumab plus ridaforolimus plus exemestane
• ganitumab plus endocrine therapy
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• Ipilimumab (10 mg/kg)
• ipilimumab plus gp100
• ipilimumab plus SoC
• tremelimumab
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab
• atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus carboplatin plus paclitaxel
• atezolizumab plus cometinib
• atezolizumab plus nab-paclitaxel
• atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
• atezolizumab plus paclitaxel
• atezolizumab plus pemetrexed and platin
• atezolizumab plus SoC
• avelumab based treatment
• avelumab alone
• avelumab plus axitinib
• avelumab plus pegylated liposomal doxorubicin
• avelumab plus SoC
• camrelizumab based treatment
• camrelizumab alone
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• durvalumab plus osimertinib
• durvalumab plus etoposide and platin
• nivolumab based treatment
• nivolumab alone
• nivolumab plus cabozantinib
• nivolumab plus SoC
• nivolumab followed by ipilimumab
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (10mg/kg) 2 weeks
• pembrolizumab (2mg/kg)
• pembrolizumab and pemetrexed plus platin
• pembrolizumab plus 5FU plus platin
• pembrolizumab plus axitinib
• pembrolizumab plus lenalidomide and dexamethasone
• pembrolizumab plus lenvatinib
• pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
• pembrolizumab plus pomalidomide and dexamethasone
• pembrolizumab plus SoC
• sintilimab based treatment
• sintilimab
• sintillimab plus SoC
• Tislelizumab
• Immune checkpoint association
• durvalumab plus tremelimumab
• durvalumab plus tremelimumab plus SoC
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• pembrolizumab plus ipilimumab
• relatlimab plus nivolumab
• Immunostimulant
• vaccine
• AE37 vaccine plus GM-CSF
• GP2 vaccine plus GM-CSF
• OBI-822/OBI-821 plus cyclophosphamide
• inetetamab plus vinorelbine
• mTOR inhibitors
• everolimus
• lenvatinib plus everolimus
• sapanisertib plus fulvestrant
• phosphoinositide 3-kinase (PI3K) inhibitor
• alpelisib based treatment
• alpelisib plus fulvestrant
• alpelisib plus letrozole
• buparlisib based treatment
• buparlisib plus fulvestrant
• buparlisib plus letrozole
• taselisib based treatment
• taselisib plus letrozole
• poly ADP-ribose polymerase (PARP) inhibitor
• niraparib
• olaparib
• rucaparib
• talazoparib
• veliparib plus paclitaxel plus carboplatin
• target therapy
• margetuximab based treatment
• margetuximab plus chemotherapy
• multikinase inhibitor
• nintedanib
• VEGF(R) inhibitor
• bevacizumab based treatment
• bevacizumab plus trastuzumab plus docetaxel
• cediranib plus fulvestrant
• lenvatinib
• lenvatinib in association

 

• All
• A EFFACER all cancer
• basal cell carcinoma
• biliary tract cancer (BTC)
• billiary tract cancer - (neo)adjuvant (NA)
• billiary tract cancer - 1st line (L1)
• billiary tract cancer - 2nd line (L2)
• cholangiocarcinoma
• breast cancer (BC)
• breast cancer - adjuvant
• breast cancer - HER2-positive
• es-BC - HER2 negative - (neo)adjuvant (NA)
• es-BC - HER2 positive - (neo)adjuvant (NA)
• la/mBC - HER2 positive
• la/mBC - HER2 positive - (neo)adjuvant (NA)
• la/mBC - HER2 positive - 1st Line (L1)
• la/mBC - HER2 positive - 2nd Line (L2)
• breast cancer - HR positive
• es-BC - HR positive - (neo)adjuvant (NA)
• es-BC - HR-positive - 1st line (L1)
• la/mBC - HR positive
• la/mBC - HR positive - (neo)adjuvant (NA)
• la/mBC - HR positive - NA - PIK3CA mutant
• la/mBC - HR-positive - 1st line (L1)
• la/mBC - HR positive - L1 - PIK3CA mutant
• la/mBC - HR-positive - 2nd line (L2)
• la/mBC - HR positive - L2 - all population
• la/mBC - HR positive - L2 - PIK3CA mutant
• breast cancer - triple negative
• es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
• es-BC - TNBC - NA - all population
• es-BC - TNBC - NA - PDL1 positive
• es-BC - Triple negatif (TNBC) - 1st line (L1)
• mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
• mBC - Triple negative (TNBC) - 1st Line (L1)
• mBC - TNBC - L1 - all population
• mBC - TNBC - L1 - PDL1 positive
• mBC-Triple negative (TNBC) - 2nd Line (L2)
• mBC - TNBC - L2 - all population
• mBC - TNBC - L2 - PDL1 positive
• metastatic/advanced - breast cancer (mBC)
• cervical cancer (CC)
• classical Hodgkin lymphoma (cHL)
• refractory classic Hodgkin lymphoma (R/R cHL)
• R/R cHL - second line or more (L2)
• colorectal cancer (CRC)
• metastatic/advanced - colorectal cancer (mCRC)
• mCRC - 1st line (L1)
• mCRC - 2nd line (L2)
• endometrial cancer
• esophageal cancer (EC)
• locally advanced - esophageal cancer (laEC)
• laEC - Neo(adjuvant) (NA)
• metastatic/advanced - esophageal cancer (mEC)
• mEC - (neo)adjuvant (NA)
• mEC - 1st line (L1)
• mEC - 2nd line (L2)
• gastric or gastroesophageal junction cancer (GC)
• locally advanced (laGC)
• laGC - (neo)adjuvant (NA)
• metastatic/advanced mGC or mGEJC
• mGC or mGEJC - 1st line (L1)
• mGC or mGEJC - L1 - all population
• mGC or mGEJC - L1 - HER2 neg/PDL1 positive
• mGC or mGEJC - L1 - HER2 negative
• mGC or mGEJC - L1 - HER2 positive
• mGC or mGEJC - L1 - PDL1 positive
• mGC or mGEJC - 2nd Line (L2)
• mGC or mGEJC - L2 - all population
• mGC or mGEJC - L2 - PDL1 positive
• mGC or mGEJC - maintenance (M)
• mGC or mGEJC - M - HER2 negative
• mGC or mGEJC - M - HER2 neg/PDL1 positive
• gene alteration defined cancer
• BRAF gene alteration defined cancer
• BRCA1/2 gene alteration defined cancer
• EGFR gene alteration defined cancer
• EGFR exon 20 insertion mutation
• FGFR (2/3) gene alteration defined cancer
• KRAS gene alteration defined cancer
• MET gene alteration defined cancer
• NTRK gene alteration
• RET gene alteration defined cancer
• glioblastoma (GB)
• metastatic glioblastoma (mGB) - 1st line (L1)
• metastatic glioblastoma (mGB) - 2nd line (L2)
• head and neck cancer squamous cell cancer (HNSCC)
• locally advanced (laHNSCC)
• laHNSCC - (neo)adjuvant (NA)
• laHNSCC - 1st line (L1)
• laHNSCC - 2nd line (L2)
• metastatic-recurrent HNSCC (mHNSCC)
• mHNSCC - (neo)adjuvant (NA)
• mHNSCC - 1st line (L1)
• mHNSCC - L1 - all population
• mHNSCC - L1 - PDL1 positive
• mHNSCC - 2nd line (L2)
• mHNSCC - L2 - all population
• mHNSCC - L2 - PDL1 negative
• mHNSCC - L2 - PDL1 positive
• hepatocell cancer (HCC)
• metastatic/advanced hepatocellular cancer (mHCC)
• mHCC - (neo)adjuvant (NA)
• mHCC - 1st line (L1)
• mHCC - 2nd line (L2)
• lung cancer : non small cell (NSCLC)
• early NSCLC - (neo)adjuvant (NA)
• eNSCLC - NA - all population
• eNSCLC - NA - EGFR mutant
• early NSCLC - 1st line (L1)
• locally advanced NSCLC - (neo)adjuvant (NA)
• laNSCLC - NA - all population
• locally advanced NSCLC - maintenance (M)
• laNSCLC - M - all population
• laNSCLC - M - EGFR mutant
• metastatic/adv NSCLC (mNSCLC) - (neo)adjuvant (NA)
• mNSCLC - NA - all population
• metastatic/adv NSCLC (mNSCLC) - maintenance (M)
• mNSCLC - M - all population
• mNSCLC - M - EGFR mutant
• mNSCLC - M - EGFR wild type
• mNSCLC - M - PDL1 positive
• metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
• mNSCLC - L1 - all population
• mNSCLC - L1 - EGFR mutant
• mNSCLC - L1 - PDL1 negative
• mNSCLC - L1 - PDL1 positive
• mNSCLC - L1 - TMB>10Mb
• non squamous cell - mNSCLC - L1
• non squamous - mNSCLC - L1 - all population
• non squamous - mNSCLC - L1 - PDL1 positive
• non squamous - mNSCLC - L1 - Wild Type (WT)
• squamous cell - mNSCLC - L1
• squamous - mNSCLC - L1 - all population
• squamous - mNSCLC - L1 - PDL1 positive
• squamous - mNSCLC - L1 - Wild Type (WT)
• metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
• mNSCLC - L2 - adenocarcinoma cell
• mNSCLC - L2 - all population
• mNSCLC - L2 - EGFR high
• mNSCLC - L2 - EGFR mutant
• mNSCLC - L2 - EGFR wild type
• mNSCLC - L2 - KRAS mutant
• mNSCLC - L2 - KRAS wild type
• mNSCLC - L2 - PDL1 negative
• mNSCLC - L2 - PDL1 positive
• non squamous cell - mNSCLC - L2
• non squamous - mNSCLC - L2 - all population
• non squamous - mNSCLC - L2 - EGFR mutant
• non squamous - mNSCLC - L2 - PDL1 positive
• non squamous - mNSCLC - L2 - wild type (WT)
• squamous cell - mNSCLC - L2
• squamous - mNSCLC - L2 - all population
• squamous - mNSCLC - L2 - PDL1 positive
• NSCLC adjuvant setting
• NSCLC neoadjuvant setting
• lung cancer : small cell (SCLC)
• Extensive stage SCLC (Es-SCLC)
• Extensive stage SCLC (Es-SCLC) - maintenance (M)
• Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
• Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
• limited stage SCLC (ls-SCLC)
• limited stage SCLC (ls-SCLC) - maintenance (M)
• limited stage SCLC (ls-SCLC) - 2nd Line (L2)
• melanoma (ML)
• metastatic/adv melanoma (mML)
• mML - (neo)adjuvant (NA)
• mML - NA - all population
• mML - NA - PDL1 positive
• mML - 1st line (L1)
• mML - L1 - all population
• mML - L1 - BRAF mutant
• mML - L1 - BRAF wild
• mML - 2nd line (L2)
• mML - L2 - all population
• mML - L2 - BRAF mutant
• mesothelioma (MS)
• malignant mesothelioma (mMS) - (neo)adjuvant (NA)
• malignant mesothelioma (mMS) - 1st line (L1)
• malignant mesothelioma (mMS) - 2nd line (L2)
• multiple myeloma
• multiple myeloma - 1st line (L1)
• multiple myeloma - 2nd line (L2)
• myofibroblastic tumors
• neurofibroma
• neutropenia
• osteosarcoma
• ovarian cancer (OC)
• metastatic/advanced OC (mOC) - (neo)adjuvant (NA)
• metastatic/advanced OC (mOC) - 1st line (L1)
• mOC - L1 - all population
• mOC - L1 - PDL1 positive
• metastatic/advanced OC (mOC) - 2nd line (L2)
• metastatic/advanced OC (mOC) - maintenance (M)
• pancreatic ductal adenocarcinoma
• PIK3CA-related overgrowth spectrum
• prostate cancer (PC)
• castration-resistant prostate cancer (CRPC)
• metastatic (mCRPC) - 1st line (L1)
• metastatic (mCRPC) - 2nd line (L2)
• metastatic, hormone-sensitive prostate cancer
• renal cell cancer (RCC)
• metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
• metastatic/advanced RCC (mRCC) - 1st line (L1)
• mRCC - L1 - PDL1 negative
• mRCC - L1 - PDL1 positive
• metastatic/advanced RCC (mRCC) - 2nd line (L2)
• sarcomas
• thyroid cancer
• urothelial cancer (UC) - bladder cancer (BC)
• metastatic/advanced UC (mUC) - 1st Line (L1)
• mUC - L1 - all population
• mUC - L1 - PDL1 positive
• metastatic/advanced UC (mUC) - 2nd Line (L2)
• mUC - L2 - all population
• mUC - L2 - PDL1 positive
• metastatic/advanced UC (mUC) - maintenance (M)
• mUC - M - all population
• mUC - M - PDL1 positive
• muscular invasive bladder cancer (MIBC)
• MIBC - (neo)adjuvant (NA)
• MIBC - NA - all population
• MIBC - NA - PDL1 positive
• non-muscle-invasive BC (NMIBC)
• NMIBC - (neo)adjuvant (NA)
• NMIBC - 1st line (L1)
• NMIBC - 2nd line (L2)

  display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study